Diabetic retinopathy is a common complication in people with type 1 and type 2 diabetes, progressing from mild, moderate, and ...

The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.

Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients with lower vision, according to a speaker here. During a presentation at ...

Faricimab is under development for the treatment of non-proliferative diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, diabetic retinopathy, ...

DR was graded according to early Treatment Diabetic Retinopathy (ETDRS ... with mild non proliferative DR (NPDR), 34 patients (17.1%) with moderate NPDR, 22 patients (11.1%) with severe NPDR ...

A recent cohort study revealed low adoption of FDA-approved AI-based diabetic retinopathy detection, with less than 5% of diabetic patients receiving ophthalmic imaging. Researchers emphasize the need ...

Global diabetic retinopathy market is anticipated to exhibit a CAGR of 6.43% during the forecast period 2024-2031 due to increasing prevalence of diabetes globally and rising demand for advanced ...

SOL-R, Ocular’s second registrational trial of AXPAXLI™ in wet AMD, as of January 10, 2024 First wet AMD registrational trial, SOL-1, completed randomization in December 2024 with topline data ...

"There is a significant unmet medical need for patients suffering from diabetic retinopathy, a leading cause of blindness in the US, and current treatment ... the data in non-proliferative ...